Canntab Therapeutics Limited (CSE:PILL-OTCQB: CTABF) Co-Founder and CFO Richard Goldstein joined Steve Darling from Proactive Vancouver on Skype to discuss the company being granted their cannabis research license from Health Canada. Goldstein talks about what this license allows Canntab to do and what their next step is.
Goldstein also told Proactive what the company plan on for the remainder of 2020.
CSE:PILL
Market: CSE
Market Cap: $12.65 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Full interview: Exactus clinches two supply agreements
Exactus Inc (OTCMKTS:EXDI) CEO Emiliano Aloi tells Proactive it has entered into a supply and distribution agreement with Ceed2Med, as well as supplying hemp to Canntab Therapeutics Limited (CSE:PILL) (OTCMKTS:CTABF). Aloi says its an exciting venture and expects to push its products with...
on 11/26/2019
2 min read
Prev article
2 min read
